Placeholder Banner

Bipartisan Bill Will Strengthen Patent Rights and Protect U.S. Leadership in Biotechnology Innovation

July 10, 2019
Media Contact
Brian Newell
202.312.9268

Washington, D.C. (July 10, 2019) – The House and Senate introduced important bipartisan legislation today that will reform the inter partes post-grant review process, bringing fairness and finality to these Patent and Trademark Office (PTO) proceedings. The bill, known as the STRONGER Patents Act, also will enhance patent quality by ensuring that all fees paid to the PTO are used for their intended purposes, and will crack down on abusive patent demand letters.

Strong intellectual property (IP) protections sustain America’s global leadership in biotechnology innovation and the creation of hundreds of thousands of high-wage, high-value jobs throughout our country. BIO has long supported the balanced and bipartisan reform proposals that were introduced today by Senator Coons, Senator Cotton, Representative Stivers, and Representative Foster, and we thank them for their leadership on this critically important issue.

“Ad hoc changes to our patent laws over the last 15 years, through legislation, agency actions, and court decisions, have severely weakened our patent system,” said Tom DiLenge, BIO’s President of Advocacy, Law & Public Policy Division. “America’s laws were once considered the gold standard for the rest of the world, now we are tied for second with 10 other economies. The bipartisan STRONGER Patents Act will address many deficiencies in the patent re-examination process, while protecting patent holders and small businesses from predatory demand letters.”

Without strong patent rights, the financing to take revolutionary biotechnology discoveries from the lab to the patient, farmer, and consumer would be unavailable. Weak or inconsistent patent protections threaten new investment in the innovation sector of our economy and, with it, the jobs and industries of the future.

BIO supports the STRONGER Patents Act and will continue to advocate for passage of legislation that better supports inventors, investors, and the people waiting for new innovations to improve their lives and their environment.

###

Discover More
Following the conclusion of the WTO 13th Ministerial Conference in Abu Dhabi, John Murphy -- BIO's Chief Policy Officer -- made the following statement: “We are encouraged that WTO Members did not agree to extend an intellectual property…
The White House just announced plans to use Bayh-Dole “march-in rights” to step in and license patent rights of drugs “developed with federal funding” to other manufacturers when the price of the drug is deemed too high. BIO's Chief Advocacy Officer…
The United States International Trade Commission (USITC) today released its “COVID-19 Diagnostics and Therapeutics: Supply, Demand, and TRIPS Agreement Flexibilities” report. The report aims to analyze various issues and information gaps concerning…